Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions

Asthma; Eosinophilic

Interventions

BIOLOGICAL

Reslizumab

Reslizumab 3,4, or 5 mg/kg IV q4 weeks

Trial Locations (1)

Firestone Institute of Respiratory Health, St Joseph's Hospital, Hamilton

All Listed Sponsors

collaborator

Teva Canada

UNKNOWN

lead

McMaster University

OTHER

NCT04710134 - Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma | Biotech Hunter | Biotech Hunter